Focus:
Oncology
-
10 August 2020 News
BMS reports positive data of Opdivo plus Yervoy in MPM
Bristol Myers Squibb (BMS) has reported positive data from the Phase III CheckMate -743 trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) in previously untreated, unresectable malignant pleural mesothelioma (MPM).
-
7 August 2020 News
Roche’s Tecentriq combination fails in Phase III breast cancer trial
Roche has reported that the combination of Tecentriq (atezolizumab) plus paclitaxel (chemotherapy) failed to meet the primary goal in the Phase III IMpassion131 clinical trial for PD-L1-positive metastatic triple-negative breast...
-
7 August 2020 News
Daiichi Sankyo and AstraZeneca partner on lung cancer trial
Daiichi Sankyo and AstraZeneca have partnered to assess patritumab deruxtecan (U3-1402) in combination with Tagrisso (osimertinib) for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC).
-
6 August 2020 News
Pfizer says Lorbrena met primary goal in lung cancer trial
Pfizer has reported positive results from the Phase III CROWN clinical trial of Lorbrena (lorlatinib) in patients with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
-
5 August 2020 News
Novartis’ Kymriah shows benefit in follicular lymphoma patients
Novartis has reported positive data from the Phase II ELARA clinical trial of Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) follicular lymphoma (FL).
-
5 August 2020 News
COVID-19 poll: Disrupted clinical trials will take six to 12 months to return to normal
The COVID-19 pandemic significantly disrupted ongoing clinical trials in various stages, with more than 1,000 trials by sponsors, collaborators, or contract research organisations having gone off the trial schedules.
-
3 August 2020 News
Innovent begins Phase I trial of cancer drug IBI322 in China
Innovent Biologics has started dosing participants in the Phase Ia/Ib CIBI322A101 clinical trial of IBI322 to treat advanced malignancies in China.
-
30 July 2020 projects
Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
Tabrecta™ (capmatinib) is the first US Food and Drug Administration (FDA)-approved therapy for the treatment of adult patients diagnosed with metastatic non-small cell lung cancer (NSCLC) whose tumours have a...
-
27 July 2020 News
Chi-Med starts Phase I hematological malignancies study
Hutchison China MediTech (Chi-Med) has started dosing participants in a Phase I clinical trial of HMPL-306 for the treatment of hematological malignancies in China.
-
16 July 2020 projects
XPOVIO (selinexor) for the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
XPOVIO® (selinexor) is the only single-agent oral therapy indicated for the treatment of patients with relapsed or refractory diffuse large b-cell lymphoma (DLBCL).